STAT+: Pharmalittle: We’re reading about FDA rejecting a rare disease drug, a warning to a Hims compounding pharmacy and more
Stat News • 2/10/2026
Summary
A bipartisan group of US lawmakers is pursuing legislation to enhance antibiotic development. Additionally, the FDA has rejected a drug for a rare disease, and a warning has been issued to a Hims compounding pharmacy.
Advertisement
Lindy Score Breakdown (V4.2)
52d
Age
1
Sources
from cluster
1246
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1246/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1246/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 52 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
STAT+: Pharmalittle: We’re reading about FDA view on peptide compounding, Iran war hurting trial recruitment, and more
Stat News • 2 days ago
STAT+: Pharmalittle: We’re reading about Trump tariff plans, FDA’s OK for a Lilly obesity pill, and more
Stat News • 1 day ago
STAT+: Insilico Medicine CEO on how best to use AI in drug development
Stat News • 2 days ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
STAT+: The biotech scorecard for the second quarter: 23 stock-moving events to watch
Stat News • 2 days ago
STAT reporter goes up against radiologists to spot deepfake X-rays
Stat News • 1 day ago
STAT+: Beyond detection: In the age of clinical AI, what counts as an FDA ‘breakthrough’ medical device?
Stat News • 1 day ago
STAT+: The HSA industry makes its MAHA pitch
Stat News • 2 days ago
STAT+: NIH director’s invocation of Vannevar Bush’s legacy to promote Trump science policies sparks pushback
Stat News • 2 days ago
STAT+: HHS changes the U.S. health IT office’s name, and its purview
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago